-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In July, the National Medical Insurance Bureau held a working forum to listen to the opinions and suggestions of relevant companies and industry associations on the reform of centralized insulin procurement
Ganli Pharmaceutical’s recombinant insulin glargine injection, Chang Xiulin, has been singing in the insulin market all the way, promoting Ganli Pharmaceutical’s official landing on the Shanghai Stock Exchange in 2020
.
In 2020, Chang Xiulin's terminal sales in China's public medical institutions were 2.
559 billion yuan, an increase of 15.
46% year-on-year, and it accounted for more than one-third of the domestic insulin glargine injection market share
.
The company has recombinant insulin lispro (fast-acting), recombinant insulin glargine (long-acting), insulin aspart and protamine zinc, recombinant insulin lispro (25R), insulin aspart 30 and protamine-human insulin mixed (30R), etc.
6 This product has become a leading company in the domestic insulin industry
.
According to the annual reports of multinational companies, the global insulin market will exceed US$21.
From 2018 to 2020, the proportion of imported brands only dropped by 1.
In the bargaining of the quantity of insulin drugs in Wuhan in 2020, centralized procurement has promoted the changes in the market structure, reflecting the trend of accelerating the substitution of imported insulin by domestically produced insulin and controlling the excessive growth of medical expenses
Domestic recombinant insulin is eye-catching
From January to July 2021, the NMPA approved 10 insulin production approval documents produced by domestic companies, which is double the number of approvals for the entire year of 2020
Insulin aspart belongs to the third generation of insulin.
According to data from Minai.
In 2020, Sanofi's total sales of insulin glargine (Lantus, Toujeo) was 3.
In 2002, Sanofi's insulin glargine entered the Chinese market under the trade name Laidushi
.
In 2005, Beijing Ganli Pharmaceutical’s Chang Xiulin was approved for production; Zhuhai Federation’s insulin glargine was approved in 2016 under the trade name You Le Ling; Tonghua Dongbao Pharmaceutical’s insulin glargine was approved at the end of 2019, under the trade name Chang Shu Lin
.
In January 2020, Chang Shulin completed the production and inspection of multiple batches, and began to put on the market in February 2020
.
According to data from Minai.
com, in 2020, the sales of insulin glargine injection in China's public medical institutions will exceed 6.
8 billion yuan, a year-on-year increase of 12.
88%
.
In the past 10 years, insulin glargine injection has maintained a growth trend
.
In the first quarter of 2021, Sanofi’s Insulin Glargine injection market in public hospitals in key provinces and municipalities accounted for 73.
02%, Chang Xiulin of Ganli Pharmaceuticals accounted for 25.
18%, and Youlerin of Zhuhai Federation accounted for 1.
81%
.
The share of domestic drugs in the market is increasing year by year
.
Ganli Pharmaceutical’s recombinant insulin glargine injection, Chang Xiulin, has been singing in the insulin market all the way, promoting Ganli Pharmaceutical’s official landing on the Shanghai Stock Exchange in 2020
.
In 2020, Chang Xiulin's terminal sales in China's public medical institutions were 2.
559 billion yuan, an increase of 15.
46% year-on-year, and it accounted for more than one-third of the domestic insulin glargine injection market share
.
The company has recombinant insulin lispro (fast-acting), recombinant insulin glargine (long-acting), insulin aspart and protamine zinc, recombinant insulin lispro (25R), insulin aspart 30 and protamine-human insulin mixed (30R), etc.
6 This product has become a leading company in the domestic insulin industry
.
Postscript <<<
Since the advent of insulin, it has experienced the development process from the first generation to the third generation, from animal insulin to human insulin, and then to recombinant human insulin analogues
.
With the decrease in the amount of animal insulin, some manufacturers have revoked production approvals.
In 2020, there are only 9 animal insulin injection approvals, a 58% decrease from 21 in 2013
.
A variety of new varieties have attracted the attention of domestic companies.
At present, the number of manufacturers entering the insulin industry has increased year by year.
The domestic reorganized insulin industry has become a situation where seven heroes are competing for hegemony, and the latecomers are launching new challenges
.
Beijing Shuanglu Pharmaceutical, Chongqing Chen'an Biopharmaceutical, Zhengda Tianqing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Jilin Huisheng Biopharmaceutical, Huaangde Biopharmaceutical, Shandong New Times Pharmaceutical, Lanzhou Biological Products Research Institute, Dongguan New products from 9 companies including Shidong Sunshine Biopharmaceutical R&D are under review and approval
.
